George Papakostas MD
Professor at Harvard Medical School and Associate Executive Director, Clinical Trials Network and Institute, Massachusetts General Hospital.
Join to view full profile
55 Fruit StS50 4 Massachusetts General HospitalBoston, MA 02114
Phone+1 617-726-6697
Fax+1 617-726-2894
Dr. Papakostas is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1999 - 2002
Steward Carney HospitalInternship, Internal Medicine, 1998 - 1999
New York University School of MedicineClass of 1998
Certifications & Licensure
MA State Medical License 2002 - 2028
American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression
- A Study of 6(S)-5-MTHF Among Serotonin Reuptake Inhibitor(SSRI)-Resistant Outpatients With Major Depressive Disorder (MDD)
- A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
Publications & Presentations
PubMed
- Association between anxious depression and clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepres...Stefania Chaikali, Clotilde Guidetti, Silvia Ioannou, Madhukar H Trivedi, Richard C Shelton
International Clinical Psychopharmacology. 2026-09-01 - Determinants of Nonspecific Response to Treatment in Randomized Controlled Trials of Major Depressive Disorder: A Narrative Review.Clotilde Guidetti, Riccardo De Giorgi, Nathan T M Huneke, Franco De Crescenzo, Chiara Zippi
The American Journal of Psychiatry. 2026-07-29 - 1 citationsDepression severity and efficacy outcomes: post hoc analyses from a phase 3 trial of esmethadone for the adjunctive treatment of major depressive disorder with inadequ...Clotilde Guidetti, George I Papakostas, Steven Stahl, Luca Pani, Sara De Martin
International Clinical Psychopharmacology. 2026-07-01
Journal Articles
- Research Paper Tachyphylaxis in Major Depressive Disorder: A Review of the Current State of ResearchGustavo Kinrys, Andrew A Nierenberg, George I Papakostas, David Mischoulon, Maurizio Fava, Marlene P Freeman, ScienceDirect
- Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD)Sanjay J Mathew, Madhukar H Trivedi, Lee C Chang, Dan V Iosifescu, Manish K Jha, Maurizio Fava, Marlene P Freeman, Cristina Cusin, James Murrough, George I Papakostas,..., Nature
Press Mentions
4 Serotonin Supplements to Treat Depression, Anxiety, & Insomnia YourselfJune 5th, 2019
Allergan’s Phase III Botox Trial for Depression Pushed to H2 2019December 10th, 2018- Major Depression ZiprasidoneOctober 6th, 2017
Grant Support
- 1/2-Ziprasidone Augmentation Of Ssris For Treatment-Resistant Depression (TRD)National Institute Of Mental Health2008–2012
- S-Adenosyl Methionine(Same)Augmentation Of Ssris In MDDNational Institute Of Mental Health2004–2008
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
